ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque ...

Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

Alumis (ALMS) announced positive 52-week data from the open-label extension, OLE, of its Phase 2 STRIDE clinical trial evaluating ESK-001 in ...

(RTTNews) - Alumis Inc. (ALMS), Friday has announced that it will present positive 52-week data from its Phase 2 open-label extension or OLE study of ESK-001, an oral TYK2 inhibitor, at the 2025 ...

Late-breaking oral presentation to highlight 52-week data of ESK-001 in a Phase 2 open-label extension (OLE) study in adults with moderate-to-severe plaque psoriasis – ...

Acelyrin and Alumis plan to close their merger in the second quarter of 2025, pending clearances and shareholder approval.

Alumis brings to the table its precision approach to clinical outcomes, with its most advanced product candidate, ESK-001, an oral inhibitor for plaque psoriasis and systemic lupus erythematosus ...

Alumis's lead product candidate, ESK-001, has demonstrated potentially best-in-class activity in a Phase 2 psoriasis (PsO) study. The company is also developing A-005, a central nervous system ...

It also started dosing patients in a mid-stage clinical trial of the same drug, called ESK-001, in crippling systemic lupus erythematosus, or SLE, the most common form of lupus. Alumis plans to ...

This merger aims to enhance financial flexibility and advance an expanded late-stage pipeline, including Alumis' ESK-001 and ACELYRIN's lonigutamab. With a pro forma cash position of roughly $737 ...